德邁仕(301007.SZ):實控人將變更為潘異 5月23日起復牌
格隆匯5月22日丨德邁仕(301007.SZ)公佈,2025年5月22日,德邁仕投資全體股東與匯心創智簽署《股權轉讓框架協議》,德邁仕投資全體股東擬向匯心創智轉讓其持有的德邁仕投資100.00%的股權,交易價格為人民幣6.691億元。
截至本協議簽署日,德邁仕投資持有公司25,650,000股股份,佔公司總股份的16.73%。若本次交易順利推進並實施完成,上市公司直接控股股東不變,匯心創智將通過控制德邁仕投資成為公司間接控股股東,公司實際控制人將由何建平先生變更為潘異先生。
公司股票(股票簡稱:德邁仕,股票代碼:301007)自2025年5月23日(星期五)開市起復牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.